High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer

an eastern cooperative oncology group protocol

Croig R. Nichols, Janet Andersen, Hillard M. Lazarus, Hugh Fisher, John Greer, Edward A. Stadtmauer, Patrick Loehrer, Donald L. Trump

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

Original languageEnglish (US)
Pages (from-to)558-563
Number of pages6
JournalJournal of Clinical Oncology
Volume10
Issue number4
StatePublished - 1992

Fingerprint

Autologous Transplantation
Germ Cell and Embryonal Neoplasms
Carboplatin
Etoposide
Bone Marrow Transplantation
Bone Marrow
Drug Therapy
Cisplatin
Kidney
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nichols, C. R., Andersen, J., Lazarus, H. M., Fisher, H., Greer, J., Stadtmauer, E. A., ... Trump, D. L. (1992). High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an eastern cooperative oncology group protocol. Journal of Clinical Oncology, 10(4), 558-563.

High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer : an eastern cooperative oncology group protocol. / Nichols, Croig R.; Andersen, Janet; Lazarus, Hillard M.; Fisher, Hugh; Greer, John; Stadtmauer, Edward A.; Loehrer, Patrick; Trump, Donald L.

In: Journal of Clinical Oncology, Vol. 10, No. 4, 1992, p. 558-563.

Research output: Contribution to journalArticle

Nichols, Croig R. ; Andersen, Janet ; Lazarus, Hillard M. ; Fisher, Hugh ; Greer, John ; Stadtmauer, Edward A. ; Loehrer, Patrick ; Trump, Donald L. / High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer : an eastern cooperative oncology group protocol. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 4. pp. 558-563.
@article{08d81d258aa448dfa138d7f7c8dc93a7,
title = "High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an eastern cooperative oncology group protocol",
abstract = "Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45{\%}) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13{\%}) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.",
author = "Nichols, {Croig R.} and Janet Andersen and Lazarus, {Hillard M.} and Hugh Fisher and John Greer and Stadtmauer, {Edward A.} and Patrick Loehrer and Trump, {Donald L.}",
year = "1992",
language = "English (US)",
volume = "10",
pages = "558--563",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer

T2 - an eastern cooperative oncology group protocol

AU - Nichols, Croig R.

AU - Andersen, Janet

AU - Lazarus, Hillard M.

AU - Fisher, Hugh

AU - Greer, John

AU - Stadtmauer, Edward A.

AU - Loehrer, Patrick

AU - Trump, Donald L.

PY - 1992

Y1 - 1992

N2 - Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

AB - Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026518779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026518779&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 558

EP - 563

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -